•
BD
BDTX
Black Diamond Therapeutics, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
146.43M
Volume
1.10M
52W High
$4.94
52W Low
$1.20
Open
$0.00
Prev Close
$2.40
Day Range
0.00 - 0.00
About Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Latest News
Black Diamond (BDTX) Q2 Loss Narrows 47%
The Motley Fool•Aug 7
Clarus (CLAR) Q2 Loss Beats Estimates
The Motley Fool•Aug 1
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
GlobeNewswire Inc.•Mar 19
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
GlobeNewswire Inc.•Jan 29
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.•Nov 5
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
GlobeNewswire Inc.•Oct 7
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
GlobeNewswire Inc.•Sep 22
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
GlobeNewswire Inc.•Sep 14